Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN2030 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered during the Double-Blind Treatment Period of 52 weeks. |
| ALXN2030 Dose A | EXPERIMENTAL | During the Double-Blind Treatment Period, participants will receive ALXN2030 dose A over 52 weeks. At Week 52, participants may continue into the Open Label Extension (OLE). |
| ALXN2030 Dose B | EXPERIMENTAL | During the Double-Blind Treatment Period, participants will receive ALXN2030 dose B over 52 weeks. At Week 52, participants may continue into the OLE Period. |
| ALXN2030 Dose C | EXPERIMENTAL | ALXN2030 will be administered as a single dose. |
| ALXN2030 Dose D | EXPERIMENTAL | ALXN2030 will be administered as a single dose. |
| ALXN2030 Dose E | EXPERIMENTAL | ALXN2030 will be administered as a single dose. |
| Name | Type | Description |
|---|---|---|
| ALXN2030 | DRUG | ALXN2030 will be administered subcutaneously (SC). |
| Placebo | DRUG | Placebo will be administered SC. |
Inclusion Criteria: * Kidney transplant received ≥ 6 months * Active or chronic active AMR according to Banff 2022 classification, based on Screening kidney biopsy * Either positive C4d on Screening kidney biopsy based on the Central Pathology Laboratory report and/or positive HLA Class I and/or II...
ALXN2030 is an investigational small molecule being studied for use in healthy participants and in patients with antibody-mediated rejection (AMR) after kidney transplantation. It is currently in Phase 2 clinical development for the AMR indication.
ALXN2030 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials of the drug in multiple countries, including the United States, United Kingdom, Brazil, Canada, China, South Korea, Spain, and Taiwan.
ALXN2030 is in Phase 2 clinical development for antibody-mediated rejection after kidney transplantation. It is also being evaluated in a Phase 1 study in healthy participants. The drug is investigational and has not been approved by regulatory authorities.
ALXN2030 is being studied in two active clinical trials. NCT05501717 is a Phase 1 study in healthy participants in the United Kingdom. NCT06744647 is a Phase 2 study in patients with antibody-mediated rejection after kidney transplantation, enrolling participants across multiple countries.
ALXN2030 is a distinct investigational drug candidate developed by AstraZeneca. No alternative names for ALXN2030 have been reported in clinical trial registrations. It is being studied under its own name in both Phase 1 and Phase 2 trials.